CliffBio
small molecule

DALVANCE

DALBAVANCIN HYDROCHLORIDE

Loss of exclusivityMay 2028latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameDALVANCE
Active ingredientDALBAVANCIN HYDROCHLORIDE
StrengthEQ 500MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMay 2014
Marketing statusRX

Listed patents

PatentExpiresType
6900175May 2028use U-3499

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DALVANCE patent cliff — loss of exclusivity May 2028 | CliffBio